Heart failure & cardiomyopathies
Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction
Authors' conclusion
LV myocardial stiffness in patients with LVH and elevated biomarkers (stage-B HFpEF) is greater than in age- and sex-matched controls and thus appears to represent a transitional state from a normal healthy heart to HFpEF.
Study context
- Population
- Middle-aged patients with left ventricular hypertrophy (LVH) and elevated cardiac biomarkers (high risk for heart failure with preserved ejection fraction (HFpEF))
- Participants
- 46 vs 61
- Exposure
- LVH with elevated cardiac biomarkers vs healthy controls
- LVHn = 46
- Controln = 61reference
- Outcome
- LV myocardial stiffness (stiffness constant, preload as transmural filling pressure)
Methodological detailsage- and sex-matched controls, right heart catheterization, 3-dimensional echocardiography, preload manipulation
- Age- and sex-matched controls
- Right heart catheterization
- 3-dimensional echocardiography
- Preload manipulation
Main finding
As reported in the abstract
LV myocardial stiffness constant
LVH
0.053
± 0.027
Control
0.042
± 0.020
P = 0.028
Observational data: associations, not effects.
Further findings
Baseline pulmonary capillary wedge pressure
P < 0.0001
Baseline pulmonary capillary wedge pressure
- Significant differences in body size and BP between groups
Original publication
Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction. Circulation. Published 23 December 2019. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →